TaiGen acquires global rights for Nemonoxacin
Following the transfer of rights, TaiGen will hold exclusive rights for development, manufacture, commercialization and sub-licensing of nemonoxacin. TaiGen originally licensed nemonoxacin product rights in ten Asian countries
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.